

Update on 31 July 2009 European Medicines Agency recommends updating the product information for Tamiflu

## **European Medicines Agency recommends updating the product information for Tamiflu**

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted recommendations to update the product information for Tamiflu with more information on the medicine's use in children over 6 months of age and in pregnant and breastfeeding women.

- For children aged from 6-12 months, the CHMP has concluded that during an influenza pandemic the benefits of the use of Tamiflu outweigh the risks and recommended the extension of the currently approved indication to include this population. The recommended dose to treat this age group is 3 mg per kg body weight twice daily for 5 days.
- For pregnant and breastfeeding women, the CHMP recommended the use of Tamiflu for treatment and post-exposure prophylaxis.

The CHMP's recommendations have been forwarded to the European Commission for the adoption of a decision. The updated product information in all EU languages for Tamiflu will be published shortly.